الرئيسية › سرطان الثدي › إلينوي › Chicago
التجارب السريرية لـ سرطان الثدي في Chicago، IL
58 دراسات لـ سرطان الثدي تبحث عن مشاركين في مواقع داخل وحول Chicago (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
جارٍ التسجيلالمرحلة 3
- Affiliated Oncologists IL, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- و 1 أخرى
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 2
- University of Illinois Cancer Center, Chicago
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
جارٍ التسجيلالمرحلة 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
جارٍ التسجيل
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
جارٍ التسجيلالمرحلة 3
- Rush University Medical Center ( Site 0079), Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
جارٍ التسجيلالمرحلة 3
- Research Site, Chicago
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
جارٍ التسجيل
- Northwestern University, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
جارٍ التسجيلالمرحلة 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- University of Chicago, Chicago
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
جارٍ التسجيلالمرحلة 3
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
جارٍ التسجيلالمرحلة 1
- University of Chicago, Chicago
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
جارٍ التسجيلالمرحلة 1/2
- Northwestern University, Chicago
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
جارٍ التسجيلالمرحلة 3
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
جارٍ التسجيلالمرحلة 2
- University of Illinois Cancer Center, Chicago
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
جارٍ التسجيلالمرحلة 3
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- و 4 أخرى
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
جارٍ التسجيلالمرحلة 2
- University of Chicago Medical Center, Chicago
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
جارٍ التسجيلالمرحلة 2
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Illinois, Chicago
ATEMPT 2.0: Adjuvant T-DM1 vs TH
جارٍ التسجيلالمرحلة 2
- The University of Chicago Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- Research Site, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
جارٍ التسجيلالمرحلة 2/3
- Local Institution - 0280, Chicago
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
جارٍ التسجيلالمرحلة 3
- Northwestern University - Northwestern Memorial Hospital, Chicago
E-Mindfulness Approaches for Living After Breast Cancer
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
- University of Illinois College of Medicine - Chicago, Chicago
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
جارٍ التسجيلالمرحلة 4
- University of Illinois, Chicago
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Northwestern University, Chicago
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Illinois Cancer Center, Chicago
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
جارٍ التسجيلالمرحلة 1
- University of Chicago Comprehensive Cancer Center, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Chicago, Chicago
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
جارٍ التسجيل
- Robert H. Lurie Comprehensive Cancer Center, Chicago
- University of Illinois Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
جارٍ التسجيلالمرحلة 2
- University of Chicago Medical Center, Chicago
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- Rush MD Anderson Cancer Center, Chicago
- و 2 أخرى
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
جارٍ التسجيلالمرحلة 1
- Northwestern Memorial Hospital, Chicago
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Chicago, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
جارٍ التسجيلدراسة رصدية
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
جارٍ التسجيل
- University of Illinois, Chicago
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Chicago Medical Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
جارٍ التسجيلالمرحلة 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
جارٍ التسجيلالمرحلة 4
- University of Chicago Medical Center, Chicago
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
جارٍ التسجيلدراسة رصدية
- Rush Cancer Center, Chicago
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Illinois, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
جارٍ التسجيلدراسة رصدية
- Massive Bio SYNERGY-AI site, Chicago
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
جارٍ التسجيلدراسة رصدية
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
جارٍ التسجيلالمرحلة 3
- John H Stroger Jr Hospital of Cook County, Chicago
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
جارٍ التسجيلالمرحلة 1
- University of Chicago Medical Center, Chicago
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
جارٍ التسجيلدراسة رصدية
- University of Illinois at Chicago, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
تجارب سرطان الثدي في مدن أخرى
- New York City, NY134 دراسات
- Houston, TX126 دراسات
- Boston, MA111 دراسات
- Nashville, TN80 دراسات
- Los Angeles, CA72 دراسات
- Edison, NJ68 دراسات
- St. Louis, MO64 دراسات
- Durham, NC63 دراسات
- Queens, NY63 دراسات
- Philadelphia, PA56 دراسات
- Dallas, TX55 دراسات
- Baltimore, MD47 دراسات
دراسات أخرى في Chicago
- سرطان الرئة غير صغير الخلايا61 دراسات
- السرطان (جميع الأنواع)51 دراسات
- السرطان النقيلي45 دراسات
- سرطان البروستاتا45 دراسات
- السمنة41 دراسات
- سرطان الرئة41 دراسات
- سرطان المبيض36 دراسات
- السكتة الدماغية34 دراسات
- سرطان القولون والمستقيم33 دراسات
- قصور القلب31 دراسات
- زيادة الوزن28 دراسات
- سرطان الخلايا الحرشفية في الرأس والرقبة26 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 05/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.